US Stock Market Move | Merck & Co., Inc. (MRK.US) rose more than 4% as Winrevair succeeded in a new mid-stage trial for lung indications.

On Tuesday, Merck & Co., Inc. (MRK.US) rose more than 4% to $96.97. The company announced on Tuesday that its FDA-approved pulmonary arterial hypertension (PH) therapy, Winrevair, met its primary endpoint in patients with pulmonary arterial hypertension, a disease characterized by elevated blood pressure in the blood vessels supplying the lungs. According to the 24-week data from its Phase 2 CADENCE study, the company stated that Winrevair reduced pulmonary vascular resistance, achieving the primary endpoint of the trial with statistical and clinical significance. This proof-of-concept study aimed to evaluate the efficacy of the injection in adult patients with pre- and post-capillary pulmonary arterial hypertension due to heart failure with preserved ejection fraction compared to placebo. The company indicated that the tolerability of Winrevair was generally consistent with established safety profile and added that it will share the results at future medical conferences and continue advancing the late-stage development of the drug in CpcPH caused by HFpEF.